polymorphic solid or solvated form of 4- 2 - 5-methyl-1- (2-naphthalenyl) -1h-pyrazol-3-yl oxy ethyl morpholine hydrochloride salt, solid form, process for preparation polymorphic phase form i, polymorphic phase form iii, polymorphic phase form ii, polymorphic phase form iv, dioxane solvate, chloroform solvate, use of polymorphic phase form ii, polymorphic phase form iii, polymorphic phase form iv, dioxane solvate or chloroform solvate, process for preparing phase 4- form of 4- 2 - 5-methyl-1- (2-naphthalenyl) -1h hydrochloride salt -pyrazol-3-yl oxy ethyl morpholine and pharmaceutical composition

摘要

polymorphic solid or solvated form of 4- [2 - [[5-methyl-1- (2-naphthalenyl) -1h-pyrazol-3-yl] oxy] ethyl] morpholine hydrochloride salt, solid form, process for preparation polymorphic phase form i, polymorphic phase form iii, polymorphic phase form ii, polymorphic phase form iv, dioxane solvate, chloroform solvate, use of polymorphic phase form ii, polymorphic phase form iii, polymorphic phase form iv, dioxane solvate or chloroform solvate, process for the preparation of phase form I of 4- [2 - [[5-methyl-1- (2-naphthalenyl) -1h- hydrochloride salt pyrazol-3-yl] oxy] ethyl] morpholine and pharmaceutical composition The present invention relates to polymorphs and solvates of 4- [2 - [[5-methyl-1- (2-naphthalenyl) -1hpyrazol-2-one hydrochloride salt. 3-yl] oxy] ethyl] morpholine (p027), process for their preparation, and pharmaceutical compositions comprising them.